Telix Pharmaceuticals Limited

Stocks

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:25 21/07/2026 BST			5-day change	1st Jan Change
15.31 ^AUD	+1.39%		-2.98%	+36.70%

07-17	RBC Downgrades Telix Pharmaceuticals to Sector Perform From Outperform, Keeps AU$18 Price Target	MT
07-17	Telix Pharmaceuticals Completes Phase Three Enrollment for Prostate Cancer Imaging Study in Japan	MT

Telix Pharmaceuticals Limited Affirms Group Earnings Guidance for the Full Year 2026

Published on 05/21/2026 at 12:43 am BST

S&P Capital IQ

Add MarketScreener to your sources

TELIX PHARMACEUTICALS LIMITED

+1.39%

Telix Pharmaceuticals Limited affirmed group earnings guidance for the full year 2026. For the year, the company affirmed full-year 2026 Group revenue guidance of USD 950 million to USD 970 million based on strong uptake of Gozellix® and continued growth from Illuccix®. This guidance also includes revenue from RLS Radiopharmacies.

Add MarketScreener to your sources

Latest news about Telix Pharmaceuticals Limited

07-17	RBC Downgrades Telix Pharmaceuticals to Sector Perform From Outperform, Keeps AU$18 Price Target	MT
07-17	Telix Pharmaceuticals Completes Phase Three Enrollment for Prostate Cancer Imaging Study in Japan	MT
07-16	Telix Pharmaceuticals Opens Radiopharmaceutical Research, Manufacturing, Treatment Facility in Melbourne	MT
07-15	Telix Pharmaceuticals Doses First Patients in Phase Two Trial for Prostate Cancer Therapy	MT
07-15	Telix Reports First Patients Dosing in Prostate Cancer Trial	MT
07-15	Telix Pharmaceuticals Limited Doses First Patients In OPTIMAL-e Phase 2 Study Evaluating TLX597-Tx For Metastatic Hormone-Sensitive Prostate Cancer	CI
07-10	ASX Biggest Losers	MT
07-03	Telix Pharmaceuticals Securing FDA Nod in Line With Expectations, Says Jefferies, Shares Down 3%	MT
07-02	Telix Pharmaceuticals Aligns with Fda to Advance Prostact Global Phase 3 Trial	CI
07-02	Telix Pharmaceuticals Says FDA Clears Path to Advance Phase 3 Study of Prostate Cancer Drug Candidate	MT
07-02	Telix Pharmaceuticals Gets US FDA Nod to Advance Phase 3 Prostate Cancer Trial	MT
06-30	Telix Pharmaceuticals Limited - Special Call
06-24	ASX Biggest Gainers	MT
06-03	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration; Shares Down 3%	MT
06-02	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration	MT

Chart Telix Pharmaceuticals Limited

Duration

Period

TLX: Dynamic Chart

Company Profile

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

Employees

1,152

Sector

Biotechnology & Medical Research

More about the company